Indications Listed in Dosage.

Dosage Adult : PO Nausea and vertigo caused by Meniere's disease; Motion sickness 50-
100 mg 3-4 times/day. Max: 400 mg/day. For prevention of motion sickness, give the 1st
dose at least 30 min before travelling. IV/IM Nausea and vertigo caused by Meniere's
disease; Motion sickness 50-100 mg 4 hrly.
Dosage Details Oral
Treatment and prophylaxis of motion sickness, Nausea and vertigo caused by
Meniere's disease
Adult: 50-100 mg 3-4 times daily. Max: 400 mg daily. For prevention of motion sickness,
1st dose to be given at least 30 min before travelling.
Child: 2-5 yr 12.5-25 mg 6-8 hrly. Max: 75 mg daily; 6-12 yr 25-50 mg 6-8 hrly. Max: 150
mg daily; 12 yr Same as adult dose. For prevention of motion sickness, 1st dose to be
given at least 30 min before travelling.

Parenteral
Treatment and prophylaxis of motion sickness, Nausea and vertigo caused by
Meniere's disease
Adult: 50-100 mg 4 hrly via IM or slow IV inj over 2 min.
Child: 1.25 mg/kg 4 times daily via IM. Max: 300 mg daily.
Administration May be taken with or without food.
Reconstitution IV: Dilute each 50 mg in 10 mL NaCl 0.9% or dextrose 5% inj.
Incompatibility Aminophylline, glycopyrronium bromide, hydrocortisone Na succinate, hydroxyzine HCl,
meglumine adipiodone, some phenothiazines, and some soluble barbiturates.
Special Precautions Patient w/ seizure disorder, angle-closure glaucoma, prostatic hyperplasia, stenosing
peptic ulcer, pyloroduodenal or bladder neck obstruction, emphysema or chronic
bronchitis, bronchial asthma, CV disease including arrhythmias, HTN. Hepatic
impairment. Childn. Pregnancy and lactation.
Adverse Drug Dizziness, drowsiness, excitement, headache, insomnia, lassitude, nervousness,
Reactions restlessness, tachycardia, anorexia, epigastric distress, nausea, xerostomia, dysuria,
blurred vision, thickening of bronchial secretion, skin rash, tinnitus, dry mouth,
incoordination, palpitation, hypotension, constipation or diarrhoea, urinary frequency;
paradoxical CNS stimulation (esp in childn).
Pregnancy Category ROUTE(S) : Parenteral/PO
(US FDA)

Category B: Either animal-reproduction studies have not demonstrated a foetal risk but
there are no controlled studies in pregnant women or animal-reproduction studies have
shown an adverse effect (other than a decrease in fertility) that was not confirmed in
controlled studies in women in the 1sttrimester (and there is no evidence of a risk in later
trimesters).
Patient Counselling This drug may cause drowsiness, if affected, do not drive or operate machinery.
Overdosage Drowsiness, dilated pupils, flushed face, excitation, hallucinations, confusion, ataxia,
intermittent clonic convulsions, coma, cardiorespiratory collapse in childn; extreme
speech and swallowing difficulty, psychosis, CNS excitation preceded by sedation,
leading to a cycle of CNS excitation, seizures and postictal depression in adult.
Management: Supportive and symptomatic treatment. Perform gastric lavage w/ an
endotracheal tube w/ cuff may be beneficial. Mechanical resp assistance may be
required. Convulsions may be treated w/ diazepam in adults and phenobarbital in childn.
Drug Interactions Increased sedation when used w/ other CNS depressants. May mask the early
 symptoms of ototoxicity when used w/ aminoglycosides or other ototoxic drugs. May
potentiate the effects of other drugs w/ anticholinergic activity (e.g. TCAs).
Food Interaction Increased sedation w/ alcohol, avoid use.
Mechanism of Action Description: Dimenhydrinate competes w/ histamine for H1-receptor sites, on effector
cells in the GI tract, blood vessels, and resp tract. It blocks chemoreceptor trigger zone,
diminishes vestibular stimulation, and depresses labyrinthine function through its central
anticholinergic activity.
Onset: 15-30 min (oral); 20-30 min (IM).
Duration: 4-6 hr.
Pharmacokinetics:
Absorption: Well absorbed.
Distribution: Widely distributed into body tissues. Crosses placenta and enters breast
milk (small amount). Volume of distribution: 3-4 L/kg. Plasma protein binding: 70-85%.
Metabolism: Extensively metabolised in the liver to diphenyl-methoxy-ethylamine,
diphenyl-methoxy-acetic, diphenyl-methoxy-N-methylamine).
Excretion: Via urine. Elimination half-life: 5-8 hr.
Storage Store between 20-25C. Protect from light.
MIMS Class Antivertigo Drugs
Manufacturer Taisho Pharmaceutical

Contents Dimenhydrinate

Indications/Uses Prevention & relief of motion sickness & treatment of vertigo, nausea or vomiting
associated w/ electroshock therapy, anaesth & surgery, labyrinthine disturbances,
radiation sickness & postfenestration syndrome.
Click to view Dramamine detailed prescribing information

Dosage/Directions for Adult 50-100 mg 3-4 times daily; childn >12 yr 50 mg (1 tab); 8-12 yr 25-50 mg to 1
Use tab; 6-8 yr 12.5-25 mg ( to tab). Doses to be taken 2-3 times daily. Prevention of
motion sickness Initially 30 min before travelling.
Click to view Dramamine detailed prescribing information

Administration May be taken with or without food.

Warnings For additional cautionary notes to warn of the potential risk of using the medicine... click
to view Dramamine detailed prescribing information

Special Precautions Usage w/ certain antibiotics may cause ototoxicity. May affect ability to drive or operate
machinery. Pregnancy & lactation.

Use In Pregnancy &

Click for Dramamine detailed prescribing information
Lactation

Adverse Reactions Drowsiness.

View ADR Monitoring Form

Preg Safety (US)

Category B: Either animal-reproduction studies have not demonstrated a foetal risk but
there are no controlled studies in pregnant women or animal-reproduction studies have
shown an adverse effect (other than a decrease in fertility) that was not confirmed in
controlled studies in women in the 1sttrimester (and there is no evidence of a risk in later
trimesters).

Storage View Dramamine storage conditions for details to ensure optimal shelf-life.

MIMS Class Antivertigo Drugs

ATC Classification R06AA02 - diphenhydramine ; Belongs to the class of aminoalkyl ethers used as
systemic antihistamines.

Regulatory
G
Classification
Presentation/Packing

Form Packing/Price

Dramamine tab 50 mg 100's (Rp120,000/pak)